Please try another search
For the nine months ended 30 September 2016, CoLucid Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 54% to $42M. Higher net loss reflects Research and Development - Balancing val increase from $13.2M to $35.1M (expense), General and Administrative - Balancing v increase of 39% to $4.5M (expense), Stock-based Compensation in R&D increase from $293K to $648K (expense).
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -12.72 | -16.34 | -13.14 | -11.3 |
Net Income | -12.66 | -16.28 | -13.06 | -11.23 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Assets | 100.97 | 42.81 | 55.26 | 65.34 |
Total Liabilities | 10.43 | 11.76 | 8.8 | 6.93 |
Total Equity | 90.54 | 31.05 | 46.46 | 58.41 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -35.34 | -22.38 | -10.34 | -21.73 |
Cash From Investing Activities | 19.5 | 8.2 | 5.78 | -36.81 |
Cash From Financing Activities | 71.4 | 0.01 | 0.06 | 86.31 |
Net Change in Cash | 55.56 | -14.17 | -4.49 | 27.77 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review